COSCIENS Biopharma Inc (CSCI)

[doogdilinger]

David Dodd, President and CEO of the Company, stated, “We are very excited about this agreement for Zoptrex™ with Rafa Laboratories. Women with advanced endometrial cancer are in need of such additional treatments, and Zoptrex™ could prove to be a significant treatment option for them. This agreement is also consistent with our strategy of leveraging our pipeline to secure future revenues with strategic development and commercial licensees for specific regions of the world. We are very pleased to have Rafa Laboratories as our licensee for the Territory. Their experience and commitment to ensuring the success of Zoptrex™ in their Territory is most assuring.”